International, Multicenter Randomized Preclinical Trials in Translational Stroke Research: It's Time to Act | Zendy

Ulrich Dirnagl | Zendy; Marc Fisher | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

International, Multicenter Randomized Preclinical Trials in Translational Stroke Research: It's Time to Act

Author(s) -

Ulrich Dirnagl,

Marc Fisher

Publication year - 2012

Publication title -

journal of cerebral blood flow and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.167

H-Index - 193

eISSN - 1559-7016

pISSN - 0271-678X

DOI - 10.1038/jcbfm.2012.51

Subject(s) - medicine , stroke (engine) , clinical trial , neuroprotection , translational research , intensive care medicine , bench to bedside , preclinical research , neuroscience , pharmacology , pathology , psychology , medical physics , mechanical engineering , engineering

Translational stroke research is in a crisis, and pharmaceutical companies continue to exit the field. Many reasons for the apparently insurmountable barrier between the bench and bedside in stroke drug development have been identified. It is time to act now to bridge the gap between preclinical and clinical studies of purported new therapies. We strongly believe that it is too early to abandon translational stroke research

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research